Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
February 25, 2000
c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity
V Arora, D C Knapp, B L Smith, et al.
Leukemia & Lymphoma
|
January 1, 1994
Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences
E Bayever, K M Haines, P L Iversen, et al.
Journal of Hematotherapy & Stem Cell Research
|
May 17, 2000
Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine
J E Mata, J D Jackson, S S Joshi, et al.
Toxicology and Applied Pharmacology
|
May 1, 1997
A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo
J E Mata, S S Joshi, B Palen, et al.
Biochemical Society Transactions
|
July 20, 2007
Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo
H M Moulton, S Fletcher, B W Neuman, et al.
Cancer Gene Therapy
|
October 15, 2011
Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function
M A Morse, A Hobeika, D Serra, et al.
Antisense Research and Development
|
January 1, 1993
Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial
E Bayever, P L Iversen, M R Bishop, et al.
Leukemia & Lymphoma
|
December 1, 1995
Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents
A G Wu, S S Joshi, W C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
M R Bishop, P L Iversen, E Bayever, et al.
Leukemia & Lymphoma
|
November 9, 2001
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells
J G Sharp, M R Bishop, B Copple, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
The Journal of Pharmacology and Experimental Therapeutics
|
February 25, 2000
c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity
V Arora, D C Knapp, B L Smith, et al.
Leukemia & Lymphoma
|
January 1, 1994
Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences
E Bayever, K M Haines, P L Iversen, et al.
Journal of Hematotherapy & Stem Cell Research
|
May 17, 2000
Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine
J E Mata, J D Jackson, S S Joshi, et al.
Toxicology and Applied Pharmacology
|
May 1, 1997
A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo
J E Mata, S S Joshi, B Palen, et al.
Biochemical Society Transactions
|
July 20, 2007
Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo
H M Moulton, S Fletcher, B W Neuman, et al.
Cancer Gene Therapy
|
October 15, 2011
Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function
M A Morse, A Hobeika, D Serra, et al.
Antisense Research and Development
|
January 1, 1993
Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial
E Bayever, P L Iversen, M R Bishop, et al.
Leukemia & Lymphoma
|
December 1, 1995
Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents
A G Wu, S S Joshi, W C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
M R Bishop, P L Iversen, E Bayever, et al.
Leukemia & Lymphoma
|
November 9, 2001
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells
J G Sharp, M R Bishop, B Copple, et al.
Page
of 8